

NCT00679341 Raw comparison:

Summary:
CHIA has 30 criteria while your personal folder has 31 criteria
Total found criteria: 30/30
Total not Found: 0/30
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Histologically or cytologically confirmed          │ Histologically or cytologically confirmed          │
│ adenocarcinoma of the breast with locally advanced │ adenocarcinoma of the breast with locally advanced │
│ or metastatic disease and a candidate for          │ or metastatic disease and a candidate for          │
│ chemotherapy                                       │ chemotherapy                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Human epidermal growth factor receptor 2           │ Human epidermal growth factor receptor 2           │
│ (HER2)-positive                                    │ (HER2)-positive                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No prior chemotherapy for their metastatic breast  │ No prior chemotherapy for their metastatic breast  │
│ cancer (MBC)                                       │ cancer (MBC)                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Measurable disease                                 │ Measurable disease                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age ≥ 18 years                                     │ Age ≥ 18 years                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For women of childbearing potential and men with   │ For women of childbearing potential and men with   │
│ partners of childbearing potential agreement to    │ partners of childbearing potential agreement to    │
│ use a highly effective non-hormonal form of        │ use a highly effective non-hormonal form of        │
│ contraception or 2 effective forms of non-hormonal │ contraception or 2 effective forms of non-hormonal │
│ contraception by the patient and/or partner        │ contraception by the patient and/or partner        │
│ Contraception use must continue for the duration   │ Contraception use must continue for the duration   │
│ of study treatment and for at least 6 months after │ of study treatment and for at least 6 months after │
│ the last dose of study treatment Male patients     │ the last dose of study treatment Male patients     │
│ whose partners are pregnant should use condoms for │ whose partners are pregnant should use condoms for │
│ the duration of the study                          │ the duration of the study                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of any chemotherapy for MBC                │ History of any chemotherapy for MBC                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ An interval of < 6 months from the completion of   │ An interval of \< 6 months from the completion of  │
│ cytotoxic chemotherapy in the neo-adjuvant or      │ cytotoxic chemotherapy in the neo-adjuvant or      │
│ adjuvant setting until the time of metastatic      │ adjuvant setting until the time of metastatic      │
│ diagnosis                                          │ diagnosis                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Trastuzumab ≤ 21 days prior to randomization       │ Trastuzumab ≤ 21 days prior to randomization       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hormone therapy < 7 days prior to randomization    │ Hormone therapy \< 7 days prior to randomization   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current peripheral neuropathy of Grade ≥ 3         │ Current peripheral neuropathy of Grade ≥ 3         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of other malignancy within the last 5      │ History of other malignancy within the last 5      │
│ years except for appropriately treated carcinoma   │ years except for appropriately treated carcinoma   │
│ in situ of the cervix non-melanoma skin carcinoma  │ in situ of the cervix non-melanoma skin carcinoma  │
│ Stage I uterine cancer or other cancers with a     │ Stage I uterine cancer or other cancers with a     │
│ similar outcome as those previously mentioned      │ similar outcome as those previously mentioned      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous radiotherapy for the treatment of         │ Previous radiotherapy for the treatment of         │
│ unresectable locally advanced or metastatic breast │ unresectable locally advanced or metastatic breast │
│ cancer is not allowed if more than 25% of marrow-  │ cancer is not allowed if more than 25% of marrow-  │
│ bearing bone has been irradiated or the last       │ bearing bone has been irradiated or the last       │
│ fraction of radiotherapy has been administered     │ fraction of radiotherapy has been administered     │
│ within approximately 3 weeks prior to              │ within approximately 3 weeks prior to              │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Brain metastases that are untreated symptomatic or │ Brain metastases that are untreated symptomatic or │
│ require therapy to control symptoms or any         │ require therapy to control symptoms or any         │
│ radiation surgery or other therapy to control      │ radiation surgery or other therapy to control      │
│ symptoms from brain metastases within 2 months     │ symptoms from brain metastases within 2 months     │
│ prior to randomization                             │ prior to randomization                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of exposure to the following cumulative    │ History of exposure to the following cumulative    │
│ doses of anthracyclines Doxorubicin or liposomal   │ doses of anthracyclines Doxorubicin or liposomal   │
│ doxorubicin > 500 mg/m^2 epirubicin > 900 mg/m^2   │ doxorubicin \> 500 mg/m\^2 epirubicin \> 900       │
│ mitoxantrone > 120mg/m^2 and idarubicin > 90       │ mg/m\^2 mitoxantrone \> 120mg/m\^2 and idarubicin  │
│ mg/m^2                                             │ \> 90 mg/m\^2                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current unstable angina                            │ Current unstable angina                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of symptomatic congestive heart failure or │ History of symptomatic congestive heart failure or │
│ ventricular arrhythmia requiring treatment         │ ventricular arrhythmia requiring treatment         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of myocardial infarction within 6 months   │ History of myocardial infarction within 6 months   │
│ prior to randomization                             │ prior to randomization                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction (LVEF) below    │ Left ventricular ejection fraction (LVEF) below    │
│ 50% within approximately 28 days prior to          │ 50% within approximately 28 days prior to          │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of decreased LVEF or symptomatic           │ History of decreased LVEF or symptomatic           │
│ congestive heart failure (CHF) with previous       │ congestive heart failure (CHF) with previous       │
│ adjuvant trastuzumab treatment                     │ adjuvant trastuzumab treatment                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cardiac troponin I ≥ 0 2 ng/mL within 28 days of   │ Cardiac troponin I ≥ 0 2 ng/mL within 28 days of   │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe dyspnea at rest because of complications of │ Severe dyspnea at rest because of complications of │
│ advanced malignancy or requiring current           │ advanced malignancy or requiring current           │
│ continuous oxygen therapy                          │ continuous oxygen therapy                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current severe uncontrolled systemic disease (eg   │ Current severe uncontrolled systemic disease (eg   │
│ clinically significant cardiovascular pulmonary or │ clinically significant cardiovascular pulmonary or │
│ metabolic disease wound healing disorders ulcers   │ metabolic disease wound healing disorders ulcers   │
│ or bone fractures)                                 │ or bone fractures)                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major surgical procedure or significant traumatic  │ Major surgical procedure or significant traumatic  │
│ injury within approximately 28 days prior to       │ injury within approximately 28 days prior to       │
│ randomization or anticipation of the need for      │ randomization or anticipation of the need for      │
│ major surgery during the course of study treatment │ major surgery during the course of study treatment │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current pregnancy or lactation                     │ Current pregnancy or lactation                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of receiving any investigational treatment │ History of receiving any investigational treatment │
│ within approximately 28 days prior to              │ within approximately 28 days prior to              │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current known infection with human                 │ Current known infection with human                 │
│ immunodeficiency virus (HIV) active hepatitis B    │ immunodeficiency virus (HIV) active hepatitis B    │
│ and/or hepatitis C virus                           │ and/or hepatitis C virus                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of intolerance (including Grade 3-4        │ History of intolerance (including Grade 3-4        │
│ infusion reaction) or hypersensitivity to          │ infusion reaction) or hypersensitivity to          │
│ trastuzumab murine proteins or docetaxel           │ trastuzumab murine proteins or docetaxel           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hypersensitivity to any of the study drugs   │ Known hypersensitivity to any of the study drugs   │
│ including the excipients or any drugs formulated   │ including the excipients or any drugs formulated   │
│ in polysorbate 80                                  │ in polysorbate 80                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Assessed by the investigator to be unable or       │ Assessed by the investigator to be unable or       │
│ unwilling to comply with the requirements of the   │ unwilling to comply with the requirements of the   │
│ protocol                                           │ protocol                                           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛